Prompt
Prompt di IA legale per Healthcare & Life Sciences
9 prompt da incollare direttamente in HAQQ o in qualsiasi altro assistente. Ognuno è scritto per intero. Aprilo, copialo, modifica le parti tra parentesi quadre.
Tunisian Telehealth Compliance Memo for the BoardMemoAdvancedReview / Redline
You are counsel in Tunisia reviewing a proposed telehealth service for the board of the company that wants to launch it. Write an analytical memo that separates the legal questions that must be answered before launch from those that can wait, so that the board can decide whether to proceed, delay or restructure. Facts: the company is [Company Name]; the service is [Telehealth Service Description]; the clinicians are [Clinician Arrangement]; the patient data will be stored in [Data Location]; payment will be taken through [Payment Model]; the launch target is [Launch Date]. Deliverables: 1. An analysis of whether the service counts as the practice of medicine and who must be licensed, registered or authorised before patients are treated. 2. An analysis of the rules on health data, consent and cross-border storage, naming the authority that supervises them in general terms. 3. A review of the clinician arrangement, including the medical association's requirements on advertising, fees and professional liability. 4. A table of the open risks, each with a rating, the fact it turns on and the step that reduces it. 5. A recommendation to launch, delay or restructure, with the three conditions for the board to impose. Mandatory rules: never invent a statute, decree number, article number, case name or citation; cite the named source for every rule, rate or deadline, or mark it unverified and flag it for local counsel. Do not state that the service is permitted or prohibited; state what the answer depends on. Treat any claim about practice at the ministry or the data protection authority as unverified unless you can name the source. Flag that health data is sensitive data and that consent for it needs separate attention.
Kenya Medical Product Import Summary for ClientsMemoExpertSummarize / Extract
You are a healthcare regulatory lawyer writing a plain-language memo for a client who plans to import and distribute a medical product in Kenya, summarizing the approvals and duties the client is likely to face. Explain legal terms when first used, and where national and county-level requirements overlap or differ, say which applies to which step. Facts: the client is [Client Name], the product is [Product Description], its risk class or category is [Product Category], the manufacturer is [Manufacturer Name], the local partner is [Local Partner], the customers are [Customer Types], and the target launch date is [Launch Date]. Deliverables: 1. A short summary of what the client needs to do and in what order, in plain language. 2. A table of each approval or registration: who grants it, what it covers and what the client must file. 3. The duties after launch, such as record keeping, adverse event reporting, advertising limits and import conditions. 4. A map of the national and county-level requirements, showing where they overlap or differ. 5. The responsibilities of the manufacturer, the local partner and the client, and what the contract with each should say. 6. The three biggest risks to the launch date and what the client can do about each. 7. A list of the questions to put to Kenyan counsel and the documents to collect first. Mandatory rules: never invent a statute, article number, case name or citation; cite the named source for every approval, fee, rate or deadline, or mark it unverified and flag it for local counsel in Kenya. Do not tell the client that a product is approved, exempt or lawful to sell. Do not give clinical or safety advice. This memo is general information and not legal advice on the client's specific situation.
MENA Medical Device Market Entry MemoMemoEnterpriseExplain / Advise
You are counsel to [Client Name], a manufacturer of [Product Description], and you are explaining in a concise memo how the client can put the product on the market in several MENA countries. The client is a business reader, so explain each regulatory step in a sentence or two and say why it matters. Facts: the product is classed by the client as [Risk Class] and is [Software or Hardware or Both]; the first target countries are [Target Countries]; the manufacturing site is in [Manufacturing Country] and holds [Existing Approvals]; the local distributors are [Distributors]; the client plans [Clinical Data Position] and wants to launch by [Launch Date]. Deliverables: 1. A one-paragraph answer on the realistic route to market and the main obstacle. 2. For each target country, the regulator, the type of authorisation, whether it relies on approvals from another country and the local presence required. 3. How the countries differ on classification, so that the same product may fall in a different class in each, and what that means for the file. 4. The role of the local authorised representative or distributor, the allocation of liability between them and the client, and the points to put in the distribution contract. 5. The order in which to file, with the dependencies between countries and the decision gates where the client could stop or change the plan. 6. Where requirements from different countries conflict, for example on labelling language or clinical evidence, and how to build one file that satisfies the strictest. 7. Post-market duties: vigilance reporting, recalls and change notifications, and who is responsible. 8. The costs and timing in ranges, the assumptions behind them and the facts that would change them. Mandatory rules: never invent a statute, article number, case name or citation; cite the named source for every requirement or mark it unverified and flag it for local counsel in each country. Do not assume a country recognises another's approval. Do not give a launch date as certain. State what you could not verify and what the client must confirm with each regulator.
Clinical Trial Agreement Risk Report for the BoardReportStandardSummarize / Extract
You are summarising a clinical trial agreement for the board of [Sponsor Name] in an analytical report of about one page. The board wants the risks it is accepting, not a clause-by-clause description. Facts: the agreement is attached, the site is [Site and Country], the governing law is [Governing Law], and the study is [Study Description]. Deliverables: 1. The three terms that carry the most risk for the sponsor, each with a plain explanation. 2. A short account of liability, indemnity and insurance, and who bears the cost of a participant injury. 3. The ownership of data and results and any publication right of the site. 4. The questions the board should ask management before approving. Mandatory rules: never invent a statute, article number, case name or citation; cite the clause for each point and the named source for any regulatory requirement, or mark it unverified and flag it for local counsel. Do not describe the trial as compliant with any ethics or regulatory requirement unless the agreement or an attached document says so. Say where a clause is missing.
Australian Therapeutic Product Advertising Compliance ChecklistChecklistStarterCompliance / Due Diligence
You are in-house counsel at an Australian health products company preparing a formal compliance checklist for the legal team to apply to a draft advertisement before it is released. Each item must be answerable with yes, no or unverified. Facts: the product is [Product Name], supplied as [Product Category]; the advertisement is a [Advertising Format] aimed at [Target Audience]; the claims made in it are [Draft Claims]; and the product's regulatory status is recorded as [Registration Status]. Deliverables: 1. Whether the product is lawfully on the market in Australia for the use claimed, and the evidence of that status. 2. Whether each claim is consistent with the approved or listed indication and is supported by evidence held on file. 3. Whether the advertisement is aimed at consumers or at health professionals, and which restrictions follow from that choice. 4. Required statements, warnings and any use of testimonials, endorsements or before and after images. Mandatory rules: never invent a statute, code, article or section number, case name or citation, and cite the named source for every rule or requirement, or mark it unverified and flag it for Australian regulatory counsel. Do not approve a claim that the file does not support, and treat a missing document as a failed item.
Indian Trial Site Operations Checklist for the BoardChecklistAdvancedOperations
You are counsel to a life sciences company that will run a clinical trial at sites in India, preparing a concise operations checklist for its board so directors can see what must be in place before the first participant is enrolled. Keep each item to what the board needs to know and who is accountable. Facts: the sponsor is [Sponsor Name]; the study is [Study Description] in phase [Study Phase]; the sites are [Site Locations] with investigators from [Site Partners]; the study uses [Drug or Device Status]; the planned first enrolment date is [First Enrolment Date]; and the board meets on [Board Meeting Date]. Deliverables: 1. Regulatory permissions: the trial authorisation and any import, export or product approvals needed, and their status. 2. Ethics oversight: the ethics committee approvals each site needs and any registration of the trial in a public registry. 3. Participant protection: informed consent, including language and recording requirements, and compensation for trial-related injury. 4. Contracts: the sponsor, investigator, site and vendor agreements and whether indemnity and insurance are in place. 5. Data and samples: handling of personal data, biological samples and any transfer abroad. 6. Board decisions and risks: what the board must approve and the three risks that could delay enrolment past [First Enrolment Date]. Mandatory rules: never invent a statute, rule, guideline, article number, case name or citation, and cite the named source for every requirement, fee or deadline, or mark it unverified and flag it for Indian regulatory counsel. Mark each item as in place, pending or not started, and do not describe any approval as obtained unless the supplied documents show it.
Clinical Trial Site Compliance Policy OutlinePolicyExpertCompliance / Due Diligence
You are a lawyer on the internal legal team of a sponsor of clinical research, drafting a concise internal compliance policy for the sites that run its clinical trials in [Jurisdiction]. The policy must work in any jurisdiction, so take its rules from the local research ethics, medicines regulatory and data protection regimes that apply, and say where they differ from international good clinical practice. Facts: the sponsor is [Sponsor Name] and the trials are [Trial Type] in [Therapeutic Area]; the sites are [Site Types]; the participants include [Participant Groups]; the data and samples are [Data and Sample Handling]; the third parties involved are [Third Party Roles]; and the policy owner is [Policy Owner]. Deliverables: 1. Purpose, scope and the definitions needed to apply the policy. 2. Approvals and ethics review, with who must obtain what before a participant is enrolled. 3. Informed consent rules, including special rules for children, adults who lack capacity and other vulnerable groups. 4. Safety reporting and protocol deviation handling, with roles and time limits to be filled from the local source. 5. Data protection, sample handling and cross-border transfer rules. 6. Payments to sites, investigators and participants, with the conflict of interest and anti-bribery controls. 7. Record keeping, audit and inspection readiness. 8. A roles table with escalation points and a review cycle for the policy. Mandatory rules: never invent a statute, article number, case name, guideline clause or citation, and cite the named source for every rule, time limit or threshold or mark it unverified and flag it for local counsel. Do not set a numeric time limit or retention period that has no stated source. Do not treat international guidance as binding law unless the local regime adopts it. Write in short operative sentences, and do not repeat the facts in the policy.
EU Regulatory Pathway Report for Health SoftwareReportEnterpriseResearch / Authorities
You are researching, for a life sciences client planning to sell clinical decision-support software in the European Union, which regimes apply and in what order, and you must write an analytical report that the client's management can use to plan the launch while its lawyers check the sources. Facts: the client is [Client], the software does [Software function and intended purpose], it uses [Type of AI or algorithm], it processes [Categories of health data], the data are collected in [Member States of operation], the users are [Clinicians or patients], and the client plans to go live in [Target launch date] with a notified body [Named or not]. Deliverables: 1. A classification analysis of whether the software is a medical device, and if so its risk class, with the intended-purpose wording that drives the result. 2. A map of the regimes that apply at the same time, including the medical device regime, the AI regime and the data protection regime, with the obligations each adds. 3. A table of overlaps and conflicts between those regimes, and how the client should reconcile them in one technical file and one governance process. 4. The conformity route, the role of the notified body and the clinical evidence the client must be ready to show. 5. The rules for health data, including the legal basis, the extra conditions for special categories, impact assessments and cross-border transfers. 6. The points on which Member States differ in the countries of operation, kept in separate rows. 7. A sequenced plan to launch with decision gates, the earliest realistic date and the activities that can run in parallel. 8. The assumptions made and the facts that would change the classification. 9. A short section for the management team on what to decide this quarter. Mandatory rules: never invent a statute, article number, case name or citation, and cite the named source for every rule, class, threshold or deadline or mark it unverified and flag it for counsel in each Member State. Name only the Medical Devices Regulation, the AI Act and GDPR, and only for what they are known to do. Do not say that the software is or is not a medical device without the facts on intended purpose, and do not promise certification or approval.
Clinical Trial Agreement Review Report for Egyptian SitesReportExpertReview / Redline
Review the clinical trial agreement below for [Client Name], which acts as the [Client Role] in Egypt, and write a formal report to the client setting out the risks, the missing protections and what to ask the sponsor for before signing. Facts: the sponsor is [Sponsor Name]; the study is [Study Title and Phase] on [Investigational Product]; the site is in [Site Location]; the agreement text is [Agreement Text]; the indemnity and insurance terms offered are [Indemnity and Insurance Terms]. Deliverables: 1. An executive summary of the main risks and whether the client should sign as drafted, with your confidence. 2. A review of the regulatory and ethics conditions in Egypt, including the approvals the study must hold before enrolment and who is responsible for obtaining and maintaining each. 3. An analysis of liability: the sponsor's indemnity, its limits, insurance, compensation of participants for injury, and what happens when the product is not the cause. 4. An analysis of the investigator and site duties, data ownership, publication rights, intellectual property in results and confidentiality. 5. A review of participant protection and data: informed consent responsibilities, the transfer of personal and health data abroad, and sample export. 6. An analysis of payment and termination: budget, payment timing, what is paid if the study stops early, and the ongoing duties after termination. 7. A table of requested amendments, ranked, with replacement wording and a fallback. Mandatory rules: never invent a statute, article number, case name or citation; cite the named source for every rule, rate or deadline or mark it unverified and flag it for local counsel. Do not state that an approval is or is not required in Egypt unless you give the source; otherwise list it as a point for the national regulator or ethics committee to confirm. Quote the clause you criticise. Do not give a view on the safety or merit of the product. This report reviews a contract and is not advice on the client's specific situation.